Humans Immortal By 2040

 

Humans Immortal By 2040

Humans Immortal By 2040

 

In 30 or 40 years, we’ll have microscopic machines traveling through our bodies, repairing damaged cells and organs, effectively wiping out diseases. The nanotechnology will also be used to back up our memories and personalities.

In an interview with Computerworld , author and futurist Ray Kurzweil said that anyone alive come 2040 or 2050 could be close to immortal. The quickening advance of nanotechnology means that the human condition will shift into more of a collaboration of man and machine , as nanobots flow through human blood streams and eventually even replace biological blood, he added.

That may sound like something out of a sci-fi movie, but Kurzweil, a member of the Inventor’s Hall of Fame and a recipient of the National Medal of Technology, says that research well underway today is leading to a time when a combination of nanotechnology and biotechnology will wipe out cancer, Alzheimer’s disease , obesity and diabetes .

It’ll also be a time when humans will augment their natural cognitive powers and add years to their lives, Kurzweil said.

“It’s radical life extension,” Kurzweil said . “The full realization of nanobots will basically eliminate biological disease and aging. I think we’ll see widespread use in 20 years of [nanotech] devices that perform certain functions for us. In 30 or 40 years, we will overcome disease and aging. The nanobots will scout out organs and cells that need repairs and simply fix them. It will lead to profound extensions of our health and longevity.”

Of course, people will still be struck by lightning or hit by a bus, but much more trauma will be repairable. If nanobots swim in, or even replace, biological blood, then wounds could be healed almost instantly. Limbs could be regrown. Backed up memories and personalities could be accessed after a head trauma.

Today, researchers at MIT already are using nanoparticles to deliver killer genes that battle late-stage cancer. The university reported just last month the nano-based treatment killed ovarian cancer, which is considered to be one of the most deadly cancers, in mice.

And earlier this year, scientists at the University of London reported using nanotechnology to blast cancer cells in mice with “tumor busting” genes, giving new hope to patients with inoperable tumors. So far, tests have shown that the new technique leaves healthy cells undamaged.

With this kind of work going on now, Kurzweil says that by 2024 we’ll be adding a year to our life expectancy with every year that passes. “The sense of time will be running in and not running out,” he added. “Within 15 years, we will reverse this loss of remaining life expectancy. We will be adding more time than is going by.”

And in 35 to 40 years, we basically will be immortal, according to the man who wrote The Age of Spiritual Machines and The Singularity is Near: When Humans Transcend Biology .

Kurzweil also maintains that adding microscopic machines to our bodies won’t make us any less human than we are today or were 500 years ago.

“The definition of human is that we are the species that goes beyond our limitations and changes who we are,” he said. “If that wasn’t the case, you and I wouldn’t be around because at one point life expectancy was 23. We’ve extended ourselves in many ways. This is an extension of who we are. Ever since we picked up a stick to reach a higher branch, we’ve extended who we are through tools. It’s the nature of human beings to change who we are.”

But that doesn’t mean there aren’t parts of this future that don’t worry him. With nanotechnology so advanced that it can travel through our bodies and affect great change on them, come dangers as well as benefits.

The nanobots, he explained, will be self-replicating and engineers will have to harness and contain that replication.

“You could have some self-replicating nanobot that could create copies of itself… and ultimately, within 90 replications, it could devour the body it’s in or all humans if it becomes a non-biological plague,” said Kurzweil. “Technology is not a utopia. It’s a double-edged sword and always has been since we first had fire.”

 

Source:  cio.com

GM corn grows horrifying tumors, 70% of females die early

Shock findings in new GMO study: Rats fed lifetime of GM corn grow horrifying tumors, 70% of females die early:

Shock findings in new GMO study: Rats fed lifetime of GM corn grow horrifying tumors, 70% of females die early

Shock findings in new GMO study: Rats fed lifetime of GM corn grow horrifying tumors, 70% of females die early

 

Eating genetically modified corn (GM corn) and consuming trace levels of Monsanto’s Roundup chemical fertilizer caused rats to develop horrifying tumors, widespread organ damage, and premature death. That’s the conclusion of a shocking new study that looked at the long-term effects of consuming Monsanto’s genetically modified corn. The study has been deemed “the most thorough research ever published into the health effects of GM food crops and the herbicide Roundup on rats.” News of the horrifying findings is spreading like wildfire across the internet, with even the mainstream media seemingly in shock over the photos of rats with multiple grotesque tumors… tumors so large the rats even had difficulty breathing in some cases. GMOs may be the new thalidomide. “Monsanto Roundup weedkiller and GM maize implicated in ‘shocking’ new cancer study” wrote The Grocery, a popular UK publication.  It reported, “Scientists found that rats exposed to even the smallest amounts, developed mammary tumors and severe liver and kidney damage as early as four months in males, and seven months for females.” The Daily Mail reported, “Fresh row over GM foods as French study claims rats fed the controversial crops suffered tumors.”  It goes on to say: “The animals on the GM diet suffered mammary tumors, as well as severe liver and kidney damage. The researchers said 50 percent of males and 70 percent of females died prematurely, compared with only 30 percent and 20 percent in the control group.”

The study, led by Gilles-Eric Seralini of the University of Caen, was the first ever study to examine the long-term (lifetime) effects of eating GMOs. You may find yourself thinking it is absolutely astonishing that no such studies were ever conducted before GM corn was approved for widespread use by the USDA and FDA, but such is the power of corporate lobbying and corporate greed.

Findings from the study

Here are some of the shocking findings from the study:

• Up to 50% of males and 70% of females suffered premature death.

• Rats that drank trace amounts of Roundup (at levels legally allowed in the water supply) had a 200% to 300% increase in large tumors.

• Rats fed GM corn and traces of Roundup suffered severe organ damage including liver damage and kidney damage.

• The study fed these rats NK603, the Monsanto variety of GM corn that’s grown across North America and widely fed to animals and humans. This is the same corn that’s in your corn-based breakfast cereal, corn tortillas and corn snack chips.

The Daily Mail is reporting on some of the reaction to the findings:

France’s Jose Bove, vice-chairman of the European Parliament’s commission for agriculture and known as a fierce opponent of GM, called for an immediate suspension of all EU cultivation and import authorisations of GM crops. ‘This study finally shows we are right and that it is urgent to quickly review all GMO evaluation processes,’ he said in a statement. ‘National and European food security agencies must carry out new studies financed by public funding to guarantee healthy food for European consumers.’

The study is entitled, “A Comparison of the Effects of Three GM Corn Varieties on Mammalian Health.”

That abstract include this text. Note: “hepatorenal toxicity” means toxic to the liver.

Our analysis clearly reveals for the 3 GMOs new side effects linked with GM maize consumption, which were sex- and often dose-dependent. Effects were mostly associated with the kidney and liver, the dietary detoxifying organs, although different between the 3 GMOs. Other effects were also noticed in the heart, adrenal glands, spleen and haematopoietic system. We conclude that these data highlight signs of hepatorenal toxicity, possibly due to the new pesticides specific to each GM corn. In addition, unintended direct or indirect metabolic consequences of the genetic modification cannot be excluded.

Here are some quotes from the researchers:

“This research shows an extraordinary number of tumors developing earlier and more aggressively – particularly in female animals. I am shocked by the extreme negative health impacts.” – Dr Michael Antoniou, molecular biologist, King’s College London.

“We can expect that the consumption of GM maize and the herbicide Roundup, impacts seriously on human health.” – Dr Antoniou.

“This is the first time that a long-term animal feeding trial has examined the impact of feeding GM corn or the herbicide Roundup, or a combination of both and the results are extremely serious. In the male rats, there was liver and kidney disorders, including tumors and even more worryingly, in the female rats, there were mammary tumors at a level which is extremely concerning; up to 80 percent of the female rats had mammary tumors by the end of the trial.” – Patrick Holden, Director, Sustainable Food Trust.

Anti-CD47 eliminates all cancer cells

One Drug to Shrink All Tumors:

 anti-CD47 in addition to chemotherapy

anti-CD47 in addition to chemotherapy

A single drug can shrink or cure human breast, ovary, colon, bladder, brain, liver, and prostate tumors that have been transplanted into mice, researchers have found. The treatment, an antibody that blocks a “do not eat” signal normally displayed on tumor cells, coaxes the immune system to destroy the cancer cells. A decade ago, biologist Irving Weissman of the Stanford University School of Medicine in Palo Alto, California, discovered that leukemia cells produce higher levels of a protein called CD47 than do healthy cells. CD47, he and other scientists found, is also displayed on healthy blood cells; it’s a marker that blocks the immune system from destroying them as they circulate. Cancers take advantage of this flag to trick the immune system into ignoring them. In the past few years, Weissman’s lab showed that blocking CD47 with an antibody cured some cases of lymphomas and leukemias in mice by stimulating the immune system to recognize the cancer cells as invaders. Now, he and colleagues have shown that the CD47-blocking antibody may have a far wider impact than just blood cancers. “What we’ve shown is that CD47 isn’t just important on leukemias and lymphomas,” says Weissman. “It’s on every single human primary tumor that we tested.” Moreover, Weissman’s lab found that cancer cells always had higher levels of CD47 than did healthy cells. How much CD47 a tumor made could predict the survival odds of a patient. To determine whether blocking CD47 was beneficial, the scientists exposed tumor cells to macrophages, a type of immune cell, and anti-CD47 molecules in petri dishes. Without the drug, the macrophages ignored the cancerous cells. But when the CD47 was present, the macrophages engulfed and destroyed cancer cells from all tumor types. Next, the team transplanted human tumors into the feet of mice, where tumors can be easily monitored. When they treated the rodents with anti-CD47, the tumors shrank and did not spread to the rest of the body. In mice given human bladder cancer tumors, for example, 10 of 10 untreated mice had cancer that spread to their lymph nodes. Only one of 10 mice treated with anti-CD47 had a lymph node with signs of cancer. Moreover, the implanted tumor often got smaller after treatment — colon cancers transplanted into the mice shrank to less than one-third of their original size, on average. And in five mice with breast cancer tumors, anti-CD47 eliminated all signs of the cancer cells, and the animals remained cancer-free 4 months after the treatment stopped. “We showed that even after the tumor has taken hold, the antibody can either cure the tumor or slow its growth and prevent metastasis,” says Weissman. Although macrophages also attacked blood cells expressing CD47 when mice were given the antibody, the researchers found that the decrease in blood cells was short-lived; the animals turned up production of new blood cells to replace those they lost from the treatment, the team reports online today in the Proceedings of the National Academy of Sciences. Cancer researcher Tyler Jacks of the Massachusetts Institute of Technology in Cambridge says that although the new study is promising, more research is needed to see whether the results hold true in humans. “The microenvironment of a real tumor is quite a bit more complicated than the microenvironment of a transplanted tumor,” he notes, “and it’s possible that a real tumor has additional immune suppressing effects.” Another important question, Jacks says, is how CD47 antibodies would complement existing treatments. “In what ways might they work together and in what ways might they be antagonistic?” Using anti-CD47 in addition to chemotherapy, for example, could be counterproductive if the stress from chemotherapy causes normal cells to produce more CD47 than usual. Weissman’s team has received a $20 million grant from the California Institute for Regenerative Medicine to move the findings from mouse studies to human safety tests. “We have enough data already,” says Weissman, “that I can say I’m confident that this will move to phase I human trials.”